Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural Production Run
25 Juin 2014 - 2:00PM
Marketwired
Itonis Pharmaceuticals Authorizes Start of Emesyl(R) Inaugural
Production Run
LAGUNA HILLS, CA--(Marketwired - Jun 25, 2014) - Itonis, Inc.
(PINKSHEETS: ITNS) Itonis is pleased to announce that, with the
finalization of its new packaging design and product labeling, it
has given the go ahead to Oasis Health Products to produce 16,000
units of its Emesyl® homeopathic product. Itonis has pre-paid
necessary funds to Oasis to commence the inaugural production
run.
"The Company is excited that we have finally developed Emesyl®
to start production. We are in good hands with Oasis Health
Products and we cannot wait for the first Emesyl® that we can
proudly market and place on store shelves," says Mark Cheung, the
Company's CEO.
About Itonis
Pharmaceuticals Itonis Pharmaceuticals, a division of
Itonis, Inc., is headed by Charles Hensley, Ph.D., and its mission
is to create and market over-the-counter and prescription
homeopathic products that better people's lives. Dr. Hensley is a
pioneer in the development and marketing of safe and effective
therapeutic nutraceutical and homeopathic preparations. He was a
founder of the company that launched the Zicam® Cold Remedy, making
the product a household name and forever changing the marketing and
product placement paradigm for homeopathic drugs in the United
States. Dr. Hensley and his team plan to use the same methodologies
to revolutionize the treatment of several other common ailments and
other chronic diseases.
About Itonis,
Inc.
Itonis, Inc. was incorporated in the state of Nevada on July 5,
2005 under the name of Kenshou, Inc., which later changed to
Itonis, Inc. on December 2, 2005. Please visit
www.itonisholdings.com.
Safe Harbor:
Statements in this press release may constitute forward-looking
statements and are subject to numerous risks and uncertainties,
including the failure to complete successfully the development of
new or enhanced products, the Company's future capital needs, the
lack of market demand for any new or enhanced products the Company
may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other
economic factors affecting the Company and its markets, seasonal
changes, and other risks detailed from time to time in the
Company's filings with the U.S. Securities and Exchange Commission.
The actual results may differ materially from those contained in
this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact: Itonis, Inc. Email Contact
Itonis (PK) (USOTC:ITNS)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
Itonis (PK) (USOTC:ITNS)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024